Genentech to Present Data From Multiple Clinical Trials on Myeloma and Other Blood Cancers
Genentech will present results on several approved or…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Clinical Trial Will Assess Immunotherapy Combo in Multiple Myeloma Patients in 2017
Adaptimmune Therapeutics and Merck have agreed to begin a…
Multiple Myeloma Patients Treated at Higher-volume Facilities Have Better Outcomes, Study Finds
Patients treated for multiple myeloma at facilities that see a…
Longer Revlimid Maintenance after Stem Cell Transplant Prolongs Myeloma Patient Survival
Longer duration of maintenance therapy with Revlimid (lenalidomide)…
Experimental Myeloma Agent Shows Promise in Combination with Immunotherapies
Inhibiting a key protein in the tumor microenvironment using…
Xgeva Matches Standard of Care in Delaying Bone Lesions in Multiple Myeloma Patients, Amgen Reports
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met…
